Logos Global Management LP Invests $4.86 Million in Rapport Therapeutics (NASDAQ:RAPP)

Logos Global Management LP bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 208,910 shares of the company’s stock, valued at approximately $4,859,000.

Several other institutional investors have also added to or reduced their stakes in the business. Sandia Investment Management LP purchased a new position in Rapport Therapeutics during the second quarter valued at approximately $116,000. Davidson Kempner Capital Management LP purchased a new stake in shares of Rapport Therapeutics in the second quarter worth $229,000. Squarepoint Ops LLC bought a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at $380,000. The Manufacturers Life Insurance Company purchased a new position in shares of Rapport Therapeutics during the 2nd quarter valued at $1,757,000. Finally, TD Asset Management Inc bought a new position in Rapport Therapeutics in the 2nd quarter worth $2,361,000.

Analyst Ratings Changes

A number of equities research analysts have commented on RAPP shares. Stifel Nicolaus started coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target on the stock. TD Cowen assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Finally, Jefferies Financial Group assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target for the company.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP opened at $20.48 on Tuesday. Rapport Therapeutics has a 52-week low of $16.55 and a 52-week high of $28.08. The company has a fifty day moving average of $20.63.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). On average, equities analysts forecast that Rapport Therapeutics will post -3.46 earnings per share for the current year.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.